WebDisclosure WebDisclosure
Basculer en Français
9504 Companies
186501 Keywords
118738 Articles
99808 Press releases
Headlines Articles Press releases UCB Remove
  1. Home
  2. Companies
  3. UCB
WebDisclosure
Basculer en Français
Headlines Articles Press releases

News

  • BRIEF

    published on 12/08/2025 at 07:45, 2 days 9 hours ago

    UCB Reports Positive Phase 3 Trial Results for Fenfluramine in CDKL5 Disorder

    UCB Phase 3 Study Fenfluramine CDKL5 Deficiency Seizure Reduction
  • BRIEF

    published on 12/08/2025 at 07:45, 2 days 9 hours ago

    UCB annonce des résultats positifs pour son essai de phase 3 sur la fenfluramine dans le traitement du syndrome CDKL5

    UCB Étude De Phase 3 Fenfluramine Déficit En CDKL5 Réduction Des Crises
  • PRESS RELEASE

    published on 12/08/2025 at 07:40, 2 days 10 hours ago

    UCB presents positive results from GEMZ phase 3 study at AES showing fenfluramine significantly reduces countable motor seizure frequency in CDKL5 Deficiency Disorder

    UCB presents positive results from GEMZ phase 3 study at AES showing significant reduction in countable motor seizure frequency in CDKL5 Deficiency Disorder. Study demonstrates efficacy and safety of fenfluramine as adjunctive treatment
    AES UCB Fenfluramine Seizure Reduction GEMZ Phase 3 Study
    Logo of UCB
Accesswire
  • Published on 12/10/2025 at 17:30, 11 minutes ago

    SMX: Industry Validation Becomes Industry Visibility

  • Published on 12/10/2025 at 16:20, 1 hour 21 minutes ago

    SMX Moves Past Proof and Into the NAFRA Room Where Implementation Begins

  • Published on 12/10/2025 at 15:10, 2 hours 31 minutes ago

    Nano One Closes $6.96 Million Overnight Marketed Offering

  • Published on 12/10/2025 at 15:00, 2 hours 41 minutes ago

    FDA Approves Renewal of Canalevia-CA1, Jaguar Health's Drug for Chemotherapy-Induced Diarrhea (CID) in Dogs

  • Published on 12/10/2025 at 14:35, 3 hours 6 minutes ago

    DataMetrex Signs Definitive Agreement to Acquire Yuzu Payment Processing Solution From Firstpayment Inc.

View all ACCESSWIRE
EQS Group
  • Published on 12/10/2025 at 17:28, 12 minutes ago

    Amundi Physical Metals plc: Final Terms

  • Published on 12/10/2025 at 17:25, 15 minutes ago

    Amundi Physical Metals plc: UK Final Terms

  • Published on 12/10/2025 at 17:19, 22 minutes ago

    Custodian Property Income REIT plc: Share Buyback

  • Published on 12/10/2025 at 16:27, 1 hour 13 minutes ago

    EQS-Adhoc: PATRIZIA SE: PATRIZIA and investors agree on long-term extension of Dawonia's mandate and scheme for realisation of exit carry

  • Published on 12/10/2025 at 16:11, 1 hour 29 minutes ago

    EQS-Adhoc: Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München: Munich Re announces new Ambition 2030 multi-year strategy and 2026 financial targets

View all EQS
Les Echos
  • Published on 12/10/2025 at 17:40, 1 minute ago

    Changes within Mersen’s Executive committee

  • Published on 12/10/2025 at 17:40, 1 minute ago

    Evolutions au sein du Comité Exécutif de Mersen

  • Published on 12/10/2025 at 08:00, 9 hours 41 minutes ago

    Neoen delivers Western Downs Battery Stage 2 and launches Stage 3 in Queensland, Australia

  • Published on 12/10/2025 at 08:00, 9 hours 41 minutes ago

    Neoen met en service la 2ème tranche et lance la construction de la 3ème tranche de Western Downs Battery dans le Queensland, en Australie

  • Published on 12/10/2025 at 07:00, 10 hours 41 minutes ago

    EURAZEO WILL ACQUIRE A MAJORITY STAKE IN WATER DIRECT TO SUPPORT NEXT PHASE OF GROWTH

View all LES ECHOS COMFI WIRE

With webdisclosure.com, you can follow all the latest financial news in real time from the best sources for companies listed on the Paris, Brussels, Amsterdam, Lisbon, Frankfurt and New York stock exchanges. You'll have access to summary articles written by us and press releases published by the companies themselves.

©Dissemination technology Webdisclosure.com - copyright 2025 SYMEX ECONOMICS all rights reserved

WebDisclosure

87, rue Ordener - 75018 Paris

Contact us

+33 1 42 23 83 61

Contact Authors Cookies policy Terms and conditions Privacy policy